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The central hypothesis of this grant is that bcl-2 protein overexpression confers intrinsic resistance to chemotherapy in patients with hormone-refractory prostate cancer (HRPC), therefore downregulation of bcl-2 protein by G3139 will enhance the antitumor activity of docetaxel in patients HRPC. We further hypothesized and the focus of the current grant application is that patients whose tumors utilize bcl-2 overexpression as a mechanism to escape the apoptotic events of chemotherapy will benefit from G3139 biomodulation, whereas tumors that exhibit other mechanisms for impaired apoptosis, such as diminished Bax expression, will fail to respond or fail to have a durable response.
The specific aims of this project are to demonstrate (1) that bcl-2 overexpression in prostate cancer specimens is a predictive biomarker for enhanced responsiveness to G3139 and docetaxel therapy; (2) that the degree of bcl-2 downregulation in normal tissue surrogate (peripheral blood mononuclear cells) will predict prostate cancer responsiveness to G3139 and docetaxel; and (3) whether the pharmacokinetic parameters of G3139 and docetaxel are predictive of bcl-2 biomodulation and antitumor activity, respectively.
Objectives:
Specific Aim 1: Demonstrate that bcl-2 overexpression in prostate cancer specimens is a predictive biomarker of enhanced responsiveness to G3139 and docetaxel therapy.
Specific Aim 2: Demonstrate that the degree of bcl-2 downregulation in normal tissue surrogate (peripheral blood mononuclear cells) will predict for the responsiveness of prostate cancer to G3139 and docetaxel.
Specific Aim 3: Determine whether the pharmacokinetic parameters of G3139 and docetaxel are predictive of bcl-2 biomodulation and antitumor activity, respectively.
Body:
Significant Accomplishments Year 3:
1. Immunohistochemical detection of protein expression for selected members of the Bcl-2 family (Bcl-2, Bax, Bcl-XL) completed on the 28 patients.
2. Examined the expression of these biomarkers and clinical outcome.
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3. Analyze and determine the relationship of these protein biomarkers as well as pharmacokinetic markers and response to Bcl-2 biomodulation by oblimersen and docetaxel.
Reportable Outcomes -Final Report (1-36 months):
The long-term goal of this grant proposal is to identify the biomarkers and pharmacologic markers that will predict which HRPC patients will respond and attain the most benefit from this mechanism-based therapeutic strategy. This proposal addresses an unmet need for the development of new therapeutic strategies for HRPC and seeks to identify which subset of patients will most benefit from this investigational therapy. Furthermore, the identification of patient subsets that would not benefit from that this therapeutic strategy would permit alternative therapeutic approaches to be developed and patients would be spared the toxicity of ineffective therapy. with docetaxel prior to the study protocol being amended and therefore these patients were excluded in the analysis to ensure that the treatment the population received was homogenous. The correlative biologic and pharmacokinetic studies are the companion to the clinical study, funded by the current Department of Defense Grant (PC010504). The accomplishments of all funded years are described below in order of the Objectives and Tasks described in the original grant application.
To meet this objective the following tasks were undertaken. respectively. This level of expression is concordant with other published reports although the level of Bcl-2 expression in this study population is modestly higher than reported by other investigators examining unselected prostate cancer populations. Since patients that entered into this study had developed hormone-refractory prostate cancer this sample may represent a selected population that exhibits this known negative prognostic indicator.
BcI-2, Bax, and Bcl-XL Protein Expression as Predictive Biomarkers of Response
To determine if Bcl-2, Bax, Bcl-XL protein expression were predictive of response to The same analysis was performed for Bax and BcI-XL. The expression of Bcl-2, Bax, and Bcl-XL protein as detected by immunohistochemistry was not predictive of PSA response to therapy with oblimersen and docetaxel in this study, with no statistically significant relationship determined for either frequency, intensity of expression, or the product (NxI).
The relationship of Bcl-2 expression and survival was next determined. In this analysis, Bcl-2 expression was grouped as either positive versus negative and survival curves plotted (Figure 1 ). Although the curves are separate, there is no significant difference between the two groups for survival at present. The limited number of events as of November 2004 may limit the ability to detect a difference currently, and analysis with longer follow-up will occur. Bcl-2 expression has been previously described as a negative prognostic variable for survival in prostate cancer. A total of 28 patients had paired mononuclear specimens were obtained from the 28 evaluable patients entered into this study. There was considerable interpatient variability in the absolute value of Bcl-2 protein obtained and this was reflected in the median normalized ratio (0.286) and the wide range of ratios (0.017-15.159).
The decrement of normalized Bcl-2 from baseline to day 6 was calculated and 19 patients had a net decrease in Bcl-2 expression whereas 9 patients had a net increase in Bcl-2 expression. The median percent decrement was 49.9% with a range of 95% decrease to 
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To determine if the decrement of MNC Bcl-2 protein may be a function of oblimersen steady state concentration (Cs,), the relationships of these two parameters were evaluated.
The mean Css ±SD of G3139 for the patients who had a decrease versus an increase in Bcl-2 expression was 5.3 ± 1.4 versus 6.1 ± 2.0 ýLg/mL, respectively. The difference of these means were not statistically significant (p = 0.24). Furthermore, no linear or non- Plasma specimens were obtained in all 28 patients for the determination of oblimersen and docetaxel pharmacokinetic parameters. Plasma concentrations for both oblimersen and docetaxel were determined using high-performance liquid chromatography methods outlined in the grant submission.
Mean (±SD) G3139 steady state concentrations for the entire group treated at 7 mg/kg/day was 5.6 (±1.6) ýig/mL.
The premise of the clinical study is that Bcl-2 downregulation will enhance the antitumor efficacy of docetaxel. To determine if the C,, of oblimersen is predictive of clinical outcome, the relationship between oblimersen C,, and antitumor response (PSA Response), time to progression, and survival were explored.
There was a significant difference between the mean C,, for patients who responded compared to those patients who did not respond. The mean (±SEM) C,, for patients who responded was 6.2 ± 0.4 compared to 4.8 ± 0.3 ýtg/mL for patients who failed to respond to treatment (p = 0.0 15). The distribution of Css and response is depicted in Figure 5 . 
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Furthermore, if the subsets of patients are divided into those patients that achieve oblimersen plasma Css > 5 ýtg/mL, the response rate for this cohort of patients was 12/16 (75%) patients whereas in the patients whose Css was less than 5 ýtg/mL the response rate was 3/12 (25%). Analysis of the impact of Css on survival indicates that the group with Css > 5 pig/mL had a median survival of 689 days versus 595 days for the patients with G3139 Css less than 5 jig/mL, although the difference did not reach statistical significance in this low powered Phase II study (Logrank test p > 0.05).
Since Oblimersen steady-state concentrations and PSA decrements are continuous variables, the relationship between these two variables for course 1 were analyzed. Oblimersen Css is a strong determinant of response in the patient population treated with the oblimersen and docetaxel combination. These results further indicate that a significant proportion of patients treated at the recommended oblimersen dose of 7mg/kg/day do not reach optimal steady state concentrations, which based on the aforementioned data appear to be at or greater than 5 ptg/mL.
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Summary and Discussion:
In the current grant that examined the predictive biomarkers of response associated with treatment with oblimersen and docetaxel, pharmacokinetic considerations (oblimersen steady state concentrations) were the strongest and only significant predictor of response to this therapy. Bcl-2, Bax and BcI-XL protein expression as detected by immunohistochemistry from the original tumor blocks and the pharmacodynamic endpoint of Bcl-2 inhibition in a normal tissue surrogate, PBMNCs, were not significant predictors of response to this therapy in hormone-refractory prostate cancer.
There are several important implications of this finding. As stated before and an original finding from this project, oblimersen Css is a statistically significant predictive of PSA response, and those patients with greater oblimersen Cs, exhibited a trend to increased survival. Furthermore, patients who achieved oblimersen Css > 5gg/mL had a 75% response rate to therapy. However, despite the administration of oblimersen at the recommended dose for solid tumor studies of 7 mg/kg/day a significant minority of patients (44% of patients) did not achieve a Qs of 5 p[g/mL or greater and may have failed to reach optimal Bcl-2 inhibitory concentrations. This may suggest that the current recommended dose used for oblimersen is suboptimal. Recent results of randomized studies in a solid tumor (melanoma) failed to reach the primary endpoint (improved survival) using the recommended dose of 7 mg/kg/day. Moreover, the premise and selection of 7 mg/kg/day in solid tumor studies may be flawed since this recommended dose was derived from a single agent Phase I study that did not determine a maximum tolerated dose, was arbitrary, and used reductions in Bcl-2 protein in PBMNCs in a limited sample of patients to justify, at least in part, the recommended dose. This unfortunately begs the question whether further clinical exploration and dose finding studies should be performed to redefine the optimal dose of oblimersen, or failing that, establishing a maximum tolerated dose prior to new clinical studies.
Additional implications of a suboptimal dose finding may confound ones ability to determine biologic predictive biomarkers such as Bcl-2 expression in the patient's original tumor tissue. If the therapy designed to inhibit Bcl-2 was not optimal, the ability to determine a predictive biomarker will no doubt be compromised. The rational next step to address this provocative finding, our group has proposed further clinical studies of oblimersen in combination with docetaxel to determine the maximum tolerated dose of oblimersen with a fixed dose of docetaxel and then determine the activity of this combination. 
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